Jennifer Zhang
The goal of this clinical trial is to study the safety, feasibility, histologic and immunological effects of Mitazalimab, a CD40 agonistic antibody, when administered either alone or in combination with PD-1 inhibition prior to surgical resection. The investigator hypothesizes that preoperative administration of CD40 agonist with or without PD-1 inhibitor intratumorally will demonstrate an acceptable safety profile, will not result in an unplanned delay in surgery, and will lead to increased immune activation. Subjects will receive a single intratumoral dose of CD40 agonist with or without PD-1 inhibitor 7 or more days prior to surgery and will be followed for safety, feasibility, immune, and pathologic responses.
Inclusion Criteria: 1. Signed and dated written IRB-approved informed consent. 2. Age ≥18 years. 3. Body weight \> 40kg 4. Stage I-III or recurrent resectable breast cancer to be treated with curative-intent 5. Planning to undergo upfront surgery as part of routine clinical care 6. Discussion with the treating or study medical oncologist re: the potential of sending an Oncotype evaluation (if ER+HER2-) on the core needle biopsy sample 7. Availability of the core needle biopsy sample for correlative studies 8. Surgery to be performed at a University of Pennsylvania Hospital 9. Life expectancy…
Intratumoral agonistic CD40
Checkpoint inhibitor
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.